Eastern Asia: Medicaments Containing Insulin Market 2024

Medicaments Containing Insulin Market Size in Eastern Asia

The East Asian medicaments containing insulin market skyrocketed to $X in 2021, with an increase of 32% against the previous year. In general, consumption, however, continues to indicate a sharp decline. The level of consumption peaked at $X in 2012; however, from 2013 to 2021, consumption stood at a somewhat lower figure.

Medicaments Containing Insulin Production in Eastern Asia

In value terms, medicaments containing insulin production dropped slightly to $X in 2021 estimated in export price. The total production indicated noticeable growth from 2012 to 2021: its value increased at an average annual rate of +3.8% over the last nine-year period. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. Based on 2021 figures, production increased by +57.3% against 2015 indices. The pace of growth appeared the most rapid in 2018 with an increase of 19% against the previous year. The level of production peaked at $X in 2020, and then contracted modestly in the following year.

Medicaments Containing Insulin Exports

Exports in Eastern Asia

In 2021, exports of medicaments containing insulin but not antibiotics in Eastern Asia surged to X tons, picking up by 527% on the previous year. Over the period under review, exports recorded a resilient expansion. The growth pace was the most rapid in 2014 when exports increased by 1,101% against the previous year. As a result, the exports attained the peak of X tons. From 2015 to 2021, the growth of the exports remained at a lower figure.

In value terms, medicaments containing insulin exports skyrocketed to $X in 2021. In general, exports, however, continue to indicate a noticeable curtailment. The pace of growth was the most pronounced in 2014 with an increase of 634%. As a result, the exports reached the peak of $X. From 2015 to 2021, the growth of the exports remained at a lower figure.

Exports by Country

Hong Kong SAR dominates exports structure, amounting to X tons, which was near 91% of total exports in 2021. It was distantly followed by China (X kg), generating a 6.2% share of total exports. Japan (X kg) took a little share of total exports.

Hong Kong SAR was also the fastest-growing in terms of the medicaments containing insulin but not antibiotics exports, with a CAGR of +70.1% from 2012 to 2021. Japan (-4.8%) and China (-14.0%) illustrated a downward trend over the same period. Hong Kong SAR (+90 p.p.) significantly strengthened its position in terms of the total exports, while Japan and China saw its share reduced by -6% and -50.1% from 2012 to 2021, respectively.

In value terms, Hong Kong SAR ($X) emerged as the largest medicaments containing insulin supplier in Eastern Asia, comprising 62% of total exports. The second position in the ranking was held by China ($X), with a 29% share of total exports.

In Hong Kong SAR, medicaments containing insulin exports expanded at an average annual rate of +99.7% over the period from 2012-2021. The remaining exporting countries recorded the following average annual rates of exports growth: China (-12.3% per year) and Japan (+5.5% per year).

Export Prices by Country

In 2021, the export price in Eastern Asia amounted to $X per ton, reducing by -76.3% against the previous year. Overall, the export price showed a abrupt curtailment. The growth pace was the most rapid in 2020 an increase of 296%. As a result, the export price attained the peak level of $X per ton, and then reduced sharply in the following year.

Prices varied noticeably by country of origin: amid the top suppliers, the country with the highest price was China ($X per ton), while Hong Kong SAR ($X per ton) was amongst the lowest.

From 2012 to 2021, the most notable rate of growth in terms of prices was attained by Hong Kong SAR (+17.4%), while the other leaders experienced more modest paces of growth.

Medicaments Containing Insulin Imports

Imports in Eastern Asia

In 2021, purchases abroad of medicaments containing insulin but not antibiotics increased by 32% to X tons, rising for the fifth consecutive year after four years of decline. Over the period under review, imports, however, continue to indicate a dramatic decline. The pace of growth was the most pronounced in 2020 with an increase of 179%. Over the period under review, imports reached the peak figure at X tons in 2012; however, from 2013 to 2021, imports failed to regain momentum.

In value terms, medicaments containing insulin imports soared to $X in 2021. In general, imports, however, recorded a sharp reduction. The most prominent rate of growth was recorded in 2020 with an increase of 423%. Over the period under review, imports reached the maximum at $X in 2012; however, from 2013 to 2021, imports failed to regain momentum.

Imports by Country

Japan prevails in imports structure, accounting for X tons, which was near 91% of total imports in 2021. It was distantly followed by China (X kg), making up a 5.1% share of total imports. South Korea (X kg) took a minor share of total imports.

Japan was also the fastest-growing in terms of the medicaments containing insulin but not antibiotics imports, with a CAGR of +32.4% from 2012 to 2021. At the same time, South Korea (+15.5%) displayed positive paces of growth. By contrast, China (-47.3%) illustrated a downward trend over the same period. Japan (+91 p.p.) and South Korea (+3.7 p.p.) significantly strengthened its position in terms of the total imports, while China saw its share reduced by -94.3% from 2012 to 2021, respectively.

In value terms, Japan ($X) constitutes the largest market for imported medicaments containing insulin but not antibiotics in Eastern Asia, comprising 96% of total imports. The second position in the ranking was held by China ($X), with a 2.6% share of total imports.

From 2012 to 2021, the average annual rate of growth in terms of value in Japan totaled +61.7%. In the other countries, the average annual rates were as follows: China (-54.2% per year) and South Korea (+59.6% per year).

Import Prices by Country

The import price in Eastern Asia stood at $X per ton in 2021, increasing by 37% against the previous year. In general, the import price, however, showed a deep downturn. The most prominent rate of growth was recorded in 2020 an increase of 87% against the previous year. The level of import peaked at $X per ton in 2014; however, from 2015 to 2021, import prices stood at a somewhat lower figure.

Prices varied noticeably by country of destination: amid the top importers, the country with the highest price was Japan ($X per ton), while South Korea ($X per ton) was amongst the lowest.

From 2012 to 2021, the most notable rate of growth in terms of prices was attained by South Korea (+38.2%), while the other leaders experienced mixed trends in the import price figures.

Source: IndexBox Platform

Frequently Asked Questions (FAQ) :